))
Capivasertib for Breast Cancer, Repotrectinib for NSCLC, Enzalutamide for Prostate Cancer, Pembrolizumab for Stomach Cancer, Hypertension Device
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on April 29, 2024 13:24 (
What now? This series will be checked again in the next hour. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 407556898 series 3561458
Konten disediakan oleh Emma Nichols, PhD and Emma Hitt Nichols. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Emma Nichols, PhD and Emma Hitt Nichols atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Check out our free downloads at nascentmc.com:
- Implementing AMA Style – 8 Things to Get Right in Your Next Project
- Needs Assessments – 7 Essentials for Getting Funded
- Working With Your Medical Writer – 8 Ways to Get the Most out of Them
See the full write ups for today's episode at nascentmc.com/podcast
Here are the highlights:
· Capivasertib (Truqap) has been FDA-approved for the treatment of hormone receptor-positive/HER2-negative breast cancer with AKT pathway alterations, showing improved progression-free survival in clinical trials.
· Repotrectinib (Augtyro) has received FDA approval for ROS1-positive non-small cell lung cancer (NSCLC), demonstrating high response rates in patients who had not received a prior tyrosine kinase inhibitor.
· Enzalutamide (Xtandi) has gained FDA approval for nonmetastatic castration-sensitive prostate cancer (nmCSPC) in high-risk patients with biochemical recurrence, expanding its use in prostate cancer treatment.
· Pembrolizumab (Keytruda) has received supplemental approval for the first-line treatment of HER2-negative stomach cancer when combined with chemotherapy, showing improved overall survival compared to chemotherapy alone.
· The Symplicity Spyral™ renal denervation (RDN) system has been approved by the FDA for treating hypertension through a minimally invasive procedure targeting overactive nerves near the kidneys.
· A combination of taurolidine and heparin catheter lock solution (DefenCath) has been approved for preventing catheter-related bloodstream infections in hemodialysis patients, demonstrating a significant reduction in infection risk in clinical trials.
Intro and outro music
48 episode
Bagikan
